ACEA Therapeutics

ʻO ACEA Therapeutics, aia ma San Diego, Kaleponi he ʻoihana nona piha ʻo Sorrento. Ua kūpaʻa ʻo ACEA Therapeutics i ka hoʻomohala ʻana a me ka hāʻawi ʻana i nā lāʻau lapaʻau hou e hoʻomaikaʻi i ke ola o nā maʻi me nā maʻi weliweli.

ʻO kā mākou hui alakaʻi, ʻo Abivertinib, kahi mea hoʻopaneʻe kinase mole liʻiliʻi, ke nānā ʻia nei e ka China Food and Drug Administration (CFDA) no ka mālama ʻana i nā poʻe maʻi me ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC) i loaʻa ka mutation EGFR T790M. Aia i loko o nā hoʻokolohua lapaʻau e mālama i nā maʻi maʻi maʻi me Covid-19 ma Brazil a me US alakaʻi ʻia e Sorrento Therapeutics. ʻO ka lua liʻiliʻi mole kinase inhibitor o ACEA, AC0058, ua komo i ka Phase 1B hoʻomohala ma US no ka mālama ʻana i ka systemic lupus erythematosus (SLE).

Me kahi hui R&D koʻikoʻi, ua hoʻokumu ʻo ACEA i ka hana lāʻau lapaʻau a me ka hiki ke kālepa ma Kina e kākoʻo i kā mākou ulu lōʻihi. Hāʻawi kēia ʻenehana iā mākou i ka mana nui ma luna o kā mākou kaulahao lako e hōʻoia i ka hāʻawi ʻia ʻana o nā huahana i nā maʻi i ka manawa.

SILEX

ʻO SCILEX HOLDING COMPANY ("Scilex") , he lālā o ka hapa nui o Sorrento, ua hoʻolaʻa ʻia i ka hoʻomohala ʻana a me ke kālepa ʻana i nā huahana hoʻoponopono ʻeha. ʻO ka huahana alakaʻi o ka hui ZTlido^® (lidocaine topical system 1.8%), he mea hōʻailona lidocaine topical huahana i ʻae ʻia e ka US Food and Drug Administration no ka hoʻomaha ʻana i ka ʻeha e pili ana me Post-Herpetic Neuralgia (PHN), ʻo ia ke ʻano o ka ʻeha aʻalolo post-shingles.

ʻO Scilex's SP-102 (10 mg dexamethasone sodium phosphate gel), a i ʻole SEMDEXA™, no ka mālama ʻana i ka ʻeha Lumbar Radicular Pain i ke kaʻina o ka hoʻopau ʻana i kahi hoʻokolohua lapaʻau Phase III. Ke manaʻo nei ka hui ʻo SP-102 ka FDA i ʻae ʻia i ka non-opioid epidural injection e mālama i ka ʻeha radicular lumbosacral, a i ʻole sciatica, me ka hiki ke hoʻololi i ka 10 i ka 11 miliona off-label epidural steroid injections i lawelawe ʻia i kēlā me kēia makahiki ma US.

Bioserv

ʻO Bioserv, aia ma San Diego, Kaleponi he ʻoihana paʻa loa ia o Sorrento. ʻIke ʻia i ka makahiki 1988, ʻo ka hui he alakaʻi alakaʻi cGMP aelike hana hoʻolako lawelawe me ka ʻoi aku o 35,000 square feet o nā hale nona nā mākaukau koʻikoʻi i kikowaena i ka aseptic a me ka non-aseptic bulk formulation; kānana; hoʻopiha; hoʻokuʻu; nā lawelawe lyophilization; lepili; ka hui ʻana o nā mea i hoʻopau ʻia; kitting a me ka paʻi ʻana; e like me ka mālama ʻana i ka mahana a me nā lawelawe hāʻawi e kākoʻo i nā huahana lāʻau Pre-Clinical, Phase I a me II Clinical Trial, nā mea hoʻoponopono lāʻau lapaʻau, nā reagents diagnostic a me nā kits, a me nā reagents ʻepekema ola.

Concortis-Levena

Ma 2008, ua hoʻokumu ʻia ʻo Concortis Biosystems me ka pahuhopu e lawelawe maikaʻi aku i ke kaiāulu ʻepekema a me ka lāʻau lapaʻau me nā kiʻekiʻe kiʻekiʻe antibody drug conjugate (ADC) reagents a me nā lawelawe. I ka makahiki 2013, ua loaʻa ʻo Sorrento iā Concortis, e hana ana i kahi hui ADC kiʻekiʻe. ʻO ka hui pū ʻana o G-MAB ™ (puke kūʻokoʻa kanaka antibody piha) me Concortis proprietary toxins, linkers, a me nā ʻano conjugation hiki ke hana i nā alakaʻi alakaʻi ʻoihana, 3rd generation ADCs.

Ke ʻimi nei ʻo Concortis ma luna o 20 mau koho ADC like ʻole (pre-clinical) me nā noi i ka oncology a ma waho. Ma ʻOkakopa 19, 2015, hoʻolaha ʻo Sorrento i ka hoʻokumu ʻana o Levena Biopharma ma ke ʻano he hui kūʻokoʻa e hāʻawi i ka mākeke i kahi ākea ākea o nā lawelawe ADC mai ka hoʻomaka ʻana o kahi papahana ADC ma o ka hana cGMP o ADC a hiki i ka pae I/II mau haʻawina hauʻoli. No ka 'ike kiko'ī, e kipa mai www.levenabiopharma.com

ʻO SmartPharm Therapeutics, Inc

ʻO SmartPharm Therapeutics, Inc Sorrento Therapeutics, Inc. (Nasdaq: SRNE), he ʻoihana biopharmaceutical pae hoʻomohala e kālele ana i ka hanauna hou, nā lāʻau lapaʻau non-viral gene no ka mālama ʻana i nā maʻi koʻikoʻi a i ʻole ka maʻi me ka ʻike o ka hana ʻana i "biologics mai loko." Ke hoʻomohala nei ʻo SmartPharm i kahi moʻolelo, DNA-encoded monoclonal antibody e pale ai i ka maʻi me SARS-CoV-2, ka maʻi i hoʻokumu ʻia ai ka COVID-19 ma lalo o kahi ʻaelike me ka Defense Advanced Research Projects Agency o ka US Department of Defense. Ua hoʻomaka ʻo SmartPharm i nā hana ma 2018 a ʻo ia ke keʻena nui ma Cambridge, MA, USA.

Ola Holoholona Ark

ʻO Ark Animal Health kahi ʻoihana paʻa o Sorrento. Ua hoʻokumu ʻia ʻo Ark i ka makahiki 2014 e lawe mai i ka mākeke holoholona hoa i nā hopena hou i hoʻopuka ʻia mai nā hana noiʻi kanaka a me ka hoʻomohala ʻana o Sorrento. Ke hoʻonohonoho ʻia nei e lilo i hui kūʻokoʻa a kūʻokoʻa ponoʻī ke hiki i ke kahua kalepa (nā huahana mākaukau e loaʻa i ka ʻae FDA).

ʻO ka papahana hoʻomohala alakaʻi o Ark (ARK-001) he hopena hoʻokahi resiniferatoxin (RTX) sterile injectable solution. Ua loaʻa iā ARK-001 ka inoa ʻo FDA CVM (Center for Veterinary Medicine) MUMS (mea hoʻohana liʻiliʻi/ʻano liʻiliʻi) no ka hoʻomalu ʻana i ka ʻeha maʻi maʻi iwi ma nā ʻīlio. Loaʻa nā papahana ʻē aʻe i nā hōʻailona hou no RTX ma nā wahi e like me ka ʻeha articular maʻi i nā holoholona hoa, ka ʻeha neuropathic i nā lio, a me ka cystitis idiopathic i nā pōpoki, a me ka ʻimi ʻana i nā manawa hoʻomohala ma kahi o nā maʻi infectious a i ʻole ka mālama ʻana i ka maʻi kanesa.

VirexHealth